This project investigates how gut microbiota and their metabolites contribute to the onset and progression of cardiometabolic diseases (CMD). By integrating large-scale metagenomic, metabolomic, and clinical datasets (e.g., SUPERB, SCAPIS, IGT), we aim to identify microbiome- and metabolite-based predictive markers and explore preventive strategies targeting microbial pathways. The analyses require substantial storage and computing resources for metagenomic assembly, functional annotation, multi-omics integration, and advanced machine learning workflows.